Feb 20, 2026Berberine for Fatty Liver Risk (MASLD): Human Trial and Meta-Analysis UpdateEvidence from randomized studies suggests berberine can improve liver fat-related markers in selected metabolic-risk groups, but protocol quality and baseline risk drive response.
Feb 15, 2026Silymarin (Milk Thistle): Liver Protection, MASLD Evidence, and Bioavailability ChallengesSilymarin (the active complex of milk thistle) has antioxidant and anti-inflammatory effects on hepatocytes. Evidence supports modest liver enzyme reduction in MASLD, though poor water solubility limits standard extract absorption. Phytosome forms show better bioavailability.
Jan 26, 2026Non-Alcoholic Fatty Liver (MASLD): Silymarin, NAC, Berberine — Evidence ReviewMASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) affects an estimated 25% of adults globally. Caloric deficit and exercise remain primary. Silymarin (milk thistle), NAC, and berberine have credible supporting evidence with consistent improvements in liver enzyme markers.